This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Erp, N. P.H. Articles by Gelderblom, H. Search for Related Content PubMed PubMed Citation Articles by van Erp, N. P.H. Articles by Gelderblom, H.

Effect of Milk Thistle (Silybum marianum) on the Pharmacokinetics of Irinotecan

Authors' Affiliations: Departments of ¹ Clinical Pharmacy and Toxicology and ² Clinical Oncology, Leiden University Medical Center, Leiden, the Netherlands; ³ The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; and ⁴ Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland

Requests for reprints: Sharyn D. Baker, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Room 1M87, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21231-1000. Phone: 410-502-7149; Fax: 410-614-9006; E-mail: sbaker7{at}jhmi.edu.

Purpose: Milk thistle (Silybum marianum) is one of the most commonly used herbal therapies, and its principal constituent silybin significantly inhibits cytochrome P450 isoform 3A4 (CYP3A4) and UDP glucuronosyltransferase isoform 1A1 (UGT1A1) in vitro. Here, we investigated whether milk thistle affects the pharmacokinetics of irinotecan, a substrate for CYP3A4 and UGT1A1, in humans.

Experimental Design: Six cancer patients were treated with irinotecan (dose, 125 mg/m²) given as a 90-minute infusion once every week. Four days before the second dose, patients received 200 mg milk thistle, thrice a day, for 14 consecutive days. Pharmacokinetic studies of irinotecan and its metabolites 7-ethyl-10-hydroxycamptothecin (SN-38), 7-ethyl-10-[3,4,5-trihydroxy-pyran-2-carboxylic acid]-camptothecin (SN-38-glucuronide), and 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin were done during the first three irinotecan administrations.

Results: Short-term (4 days) or more prolonged intake of milk thistle (12 days) had no significant effect on irinotecan clearance (mean, 31.2 versus 25.4 versus 25.6 L/h; P = 0.16). The area under the curve ratio of SN-38 and irinotecan was slightly decreased by milk thistle (2.58% versus 2.23% versus 2.17%; P = 0.047), whereas the relative extent of glucuronidation of SN-38 was similar (10.8 versus 13.5 versus 13.1; P = 0.64). Likewise, the area under the curve ratio of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]-carbonyloxycamptothecin and irinotecan was unaffected by milk thistle (0.332 versus 0.285 versus 0.337; P = 0.53). The maximum plasma concentrations of silybin ranged between 0.0249 and 0.257 µmol/L.

Conclusions: Silybin concentrations after intake of milk thistle are too low to significantly affect the function of CYP3A4 and UGT1A1 in vivo, indicating that milk thistle is unlikely to alter the disposition of anticancer drugs metabolized by these enzymes.

This article has been cited by other articles:

				P. Jancova, E. Anzenbacherova, B. Papouskova, K. Lemr, P. Luzna, A. Veinlichova, P. Anzenbacher, and V. Simanek Silybin Is Metabolized by Cytochrome P450 2C8 in Vitro Drug Metab. Dispos., November 1, 2007; 35(11): 2035 - 2039. [Abstract] [Full Text] [PDF]

				C. Tamayo and S. Diamond Review of Clinical Trials Evaluating Safety and Efficacy of Milk Thistle (Silybum marianum [L.] Gaertn.) Integr Cancer Ther, June 1, 2007; 6(2): 146 - 157. [Abstract] [PDF]

				S. Mirkov, B. J. Komoroski, J. Ramirez, A. Y. Graber, M. J. Ratain, S. C. Strom, and F. Innocenti Effects of Green Tea Compounds on Irinotecan Metabolism Drug Metab. Dispos., February 1, 2007; 35(2): 228 - 233. [Abstract] [Full Text] [PDF]

				M. Tascilar, F. A. de Jong, J. Verweij, and R. H. J. Mathijssen Complementary and Alternative Medicine During Cancer Treatment: Beyond Innocence Oncologist, July 1, 2006; 11(7): 732 - 741. [Abstract] [Full Text] [PDF]